Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of tyrosine kinase-independent phosphorylation of EGFR with activating mutation in cisplatin-treated lung cancer cells.

Biochemical and biophysical research communications - 20 Mar 2015

Refaat Alaa, Aminullah, Zhou Yue, Kawanishi Miho, Tomaru Rika, Abdelhamed Sherif, Shin Myoung-Sook, Koizumi Keiichi, Yokoyama Satoru, Saiki Ikuo, Sakurai Hiroaki

Abstract excerpt

Epidermal growth factor receptor (EGFR) mutation is one of the hallmarks of cancer progression and resistance to anticancer therapies, particularly non-small cell lung carcinomas (NSCLCs). In contrast to the canonical EGFR activation in which tyrosine residues are engaged, we have demonstrated that the non-canonical pathway is triggered by phosphorylation of serine and threonine residues through p38 and ERK...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Cisplatin

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to MAP Kinase Signaling System

Source

Identifiers

PMID: 25701783
DOI: 10.1016/j.bbrc.2015.02.044

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of tyrosine kinase-independent phosphorylation of EGFR with activating mutation in cisplatin-treated lung cancer cells.PMID 25701783Read ↗

Enhanced Efficacy of EGFR-Targeted ADCs via p38-Mediated Noncanonical Endocytosis in EGFR-Mutant Lung Cancer Cells.Semantic proximity Read ↗

Ligand-Independent EGFR Signaling.Semantic proximity Read ↗

Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer.Semantic proximity Read ↗

Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.Semantic proximity Read ↗

Multiple post-translational modifications ensure EGFR functionality: Potential therapeutic targets to overcome its drug-resistance mutations.Semantic proximity Read ↗

TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.Semantic proximity Read ↗

The molecular and clinical verification of therapeutic resistance via the p38 MAPK-Hsp27 axis in lung cancerSemantic proximity Read ↗

Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLCSemantic proximity Read ↗

Antitumor impact of p14ARF on gefitinib-resistant non-small cell lung cancers.Semantic proximity Read ↗

The effect of acquired cisplatin resistance on sensitivity to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer cells.Semantic proximity Read ↗

Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation.Semantic proximity Read ↗

Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.